Publications by authors named "S Kuemmel"

Claim this Profile
A
A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.
Javier Cortés, Araceli Priego, Elena Garralda, Katerin Rojas, Simon R Lord, Sherko Kuemmel

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.
S Kuemmel, K H Jung, L Andrade, D Assad-Suzuki, L de la Cruz Merino

ESMO Open· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding "Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer" by Chen et al.
Oleg Gluz, Ronald Kates, Sherko Kuemmel, Ulrike Nitz, Nadia Harbeck

Ann Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiomic factor analysis for pathologic complete response after pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: WSG-Keyriched-1 trial.
Monika Graeser, Oleg Gluz, Peter Schmid, Katarzyna Jóźwiak, Christine Zu Eulenburg, Sherko Kuemmel

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
Daniel Kates-Harbeck, Hans Kreipe, Oleg Gluz, Matthias Christgen, Sherko Kuemmel

JCO Clin Cancer Inform· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis